Endogenous Mucosal Antiviral Factors of the Oral Cavity
- 1 May 1999
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 179 (s3), S431-S435
- https://doi.org/10.1086/314799
Abstract
The oral cavity represents a unique site for mucosal transmission of human immunodeficiency virus type 1 (HIV-1). Unlike other mucosal sites, the oral cavity is rarely a site of HIV transmission despite detectable virus in saliva and oropharyngeal tissues of infected persons. One reason for this apparent paradox is the presence of endogenous mucosal antiviral factors. Innate inhibitory molecules, such as virus-specific antibodies, mucins, thrombospondin, and soluble proteins, have been identified and partially characterized from saliva. A recent addition to the growing list is secretory leukocyte protease inhibitor (SLPI), an ∼12-kDa non-glycosylated protein found in serous secretions. Physiologic concentrations of SLPI potently protect adherent monocytes and activated peripheral blood mononuclear cells against HIV-1 infection. SLPI levels in saliva and semen but not breast milk approximate levels required for inhibition in vitro. Characterization of SLPI and other endogenous antiviral molecules may enhance our understanding of factors influencing mucosal HIV-1 transmission.Keywords
This publication has 30 references indexed in Scilit:
- Identification of a CD36-related Thrombospondin 1–binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1–specific Inhibitory Factors in Human SalivaThe Journal of Experimental Medicine, 1998
- Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type 1Oral Diseases, 1997
- Secretory leukocyte protease inhibitor (SLPI) in mucosal fluids inhibits HIV‐1Oral Diseases, 1997
- Mucosal Immune Responses in Four Distinct Compartments of Women Infected with Human Immunodeficiency Virus Type 1: A Comparison by Site and Correlation with Clinical InformationThe Journal of Infectious Diseases, 1997
- Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteersAIDS, 1995
- Functions of the N-Terminal Domain of Secretory Leukoprotease InhibitorBiochemistry, 1994
- Characteristics of IgA Antibodies Against HIV-1 in Sera and Saliva from HIV-Seropositive Individuals in Different Clinical StagesScandinavian Journal of Immunology, 1993
- Both IgA subclasses are reduced in parotid saliva from patients with AIDSClinical and Experimental Immunology, 1991
- HIV excretion patterns and specific antibody responses in body fluidsJournal of Medical Virology, 1990
- Tissue distribution of antileukoprotease and lysozyme in humans.Journal of Histochemistry & Cytochemistry, 1989